Artivion (AORT) Cash from Financing Activities (2010 - 2026)
Artivion's (AORT) quarterly Cash from Financing Activities came in at $463000.0 in Q1 2026, down 88.24% YoY from $3.9 million in Q1 2025, and down 80.95% on a QoQ basis from $2.4 million in Q4 2025.
Artivion (AORT) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Artivion (AORT) has 17 years of Cash from Financing Activities data on file, last reported at $463000.0 in Q1 2026.
- Quarterly Cash from Financing Activities fell 88.24% year-over-year to $463000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.8 million (up 44.51% YoY) and the FY2025 annual result came in at $11.3 million, up 412.12% from the prior year.
- Cash from Financing Activities fell to $463000.0 in Q1 2026, from $2.4 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $3.9 million in Q1 2025 to a low of -$1.6 million in Q4 2023.
- A 5-year average of $774941.2 and a median of $463000.0 in 2026 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities sank 460.71% — and 2025, when it surged 1535.36%.
- Tracing AORT's Cash from Financing Activities over 5 years: stood at -$859000.0 in 2022, then tumbled by 89.76% to -$1.6 million in 2023, then soared by 110.67% to $174000.0 in 2024, then soared by 1296.55% to $2.4 million in 2025, then sank by 80.95% to $463000.0 in 2026.
- The last three Cash from Financing Activities figures came in at $463000.0 (Q1 2026), $2.4 million (Q4 2025), and $2.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | -3.52 Bn |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | -95.00 Mn |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | -410.00 Mn |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | -300,000.00 |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | -607.30 Mn |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | -236.00 Mn |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | -1.34 Bn |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | -213.50 Mn |
| 10 | Artivion | 1.36 Bn | 1.28 Bn | 80.52 Mn | 152.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 152.39 Mn |
| Jun 30, 2026 | 152.39 Mn |
| Mar 31, 2026 | 463,000.00 |
| Mar 31, 2026 | 463,000.00 |
| Dec 31, 2025 | 2.43 Mn |
| Dec 31, 2025 | 2.43 Mn |
| Sep 30, 2025 | 2.32 Mn |
| Sep 30, 2025 | 2.32 Mn |
| Jun 30, 2025 | 2.60 Mn |
| Jun 30, 2025 | 2.60 Mn |
| Mar 31, 2025 | 3.94 Mn |
| Mar 31, 2025 | 3.94 Mn |
| Dec 31, 2024 | 174,000.00 |
| Dec 31, 2024 | 174,000.00 |
| Sep 30, 2024 | 1.47 Mn |
| Sep 30, 2024 | 1.47 Mn |
| Jun 30, 2024 | -181,000.00 |
| Jun 30, 2024 | -181,000.00 |
| Mar 31, 2024 | 737,000.00 |
| Mar 31, 2024 | 737,000.00 |